Journal
BLOOD
Volume 118, Issue 7, Pages 1979-1988Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-02-337329
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [U24-CA76518, 5U01HL069294]
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Allos Inc
- Astellas Pharma US Inc
- Be the Match Foundation
- Biogen IDEC
- Bio-Marin Pharmaceutical Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix GmbH
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Eisai Inc
- Genentech Inc
- Genzyme Corporation
- Histogenetics Inc
- HKS Medical Information Systems
- Hospira Inc.
- Kirin Brewery Co Ltd
- Leukemia & Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- Millennium Pharmaceuticals Inc
- Miller Pharmacal Group
- Milliman USA Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Nature Publishing Group
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics Inc
- Otsuka America Pharmaceutical Inc
- Pall Life Sciences
- Pfizer Inc
- Schering Corporation
- Sigma-Tau Pharmaceuticals
- Soligenix Inc
- StemCyte Inc
- StemSoft Software Inc
- Sysmex America Inc
- THERAKOS Inc
- Vidacare Corporation
- ViraCor Laboratories
- ViroPharma Inc
- Wellpoint Inc.
Ask authors/readers for more resources
Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 20012005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%31%), and 3% (range, 0%-11%), respectively (P < .0001). (Blood. 2011;118(7):1979-1988)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available